Active substance
Pilocarpine
- SFDA 8
- US FDA 17
- Health Canada 5
- US price lines 9
- NHS prices 5
- WHO EML 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| APICARPINE 2% EYE DROPS | 2 % | Eye drops · Ophthalmic use | 1 Dropper Container | SAR 4.05 | Generic · Prescription | Amman Pharmaceutical Industries (API) | Valid |
| APICARPINE 4% EYE DROPS | 4 % | Eye drops · Ophthalmic use | 1 Dropper Container | SAR 7.75 | Generic · Prescription | Amman Pharmaceutical Industries (API) | Valid |
| ISOPTO CARPIN 2% EYE DROPS | 2 % | Eye drops, solution · Ocular use | 1 Dropper Container | SAR 8.95 | NCE · Prescription | ALCON LABORATORIES | Withdrawn by MAH · Not Marketed |
| ISOPTO CARPINE 1% EYE DROPS | 1 % | Eye drops, solution · Ocular use | 1 Dropper Container | SAR 9.95 | Generic · Prescription | ALCON COUVREUR | Withdrawn by MAH · Not Marketed |
| ISOPTO CARPINE 4% EYE DROPS | 4 % | Eye drops, solution · Ocular use | 1 Dropper Container | SAR 10.35 | Generic · Prescription | ALCON COUVREUR | Withdrawn by MAH · Not Marketed |
| MINIMS PILOCARPINE 2% | 2 % | Eye drops, solution · Ophthalmic use | 20 Single Dose Container | SAR 22.35 | Generic · Prescription | CHAUVIN BAUSCH & LOMB | Withdrawn by regulatory authority · Not Marketed |
| PILOTINA-2 | 2 % | Eye drops, solution · Ocular use | 1 Dropper Container | SAR 6.30 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| PILOTINA-4 | 4 % | Eye drops, solution · Ocular use | 1 Dropper Container | SAR 8.75 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
OPEN ANGLE GLUCOMA; SJOGREN'S SYNDROME
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SALAGEN | 5MG; 7.5MG | tablet · oral | ADVANZ PHARMA | Prescription | 22 Mar 1994 |
| PILOCARPINE HYDROCHLORIDE | 5MG; 7.5MG | tablet · oral | INNOGENIX | Prescription | 22 Dec 2004 |
| PILOCARPINE HYDROCHLORIDE | 5MG; 7.5MG | tablet · oral | LANNETT CO INC | Prescription | 14 Oct 2005 |
| PILOCARPINE HYDROCHLORIDE | 5MG; 7.5MG | tablet · oral | IMPAX LABS | Prescription | 31 Mar 2006 |
| ISOPTO CARPINE | 1%; 2%; 4% | solution/drops · ophthalmic | SANDOZ | Prescription | 22 Jun 2010 |
| PILOCARPINE HYDROCHLORIDE | 1%; 2%; 4% | solution/drops · ophthalmic | RISING | Prescription | 27 Sep 2017 |
| PILOCARPINE HYDROCHLORIDE | 5MG; 7.5MG | tablet · oral | QUAGEN | Prescription | 13 Aug 2019 |
| PILOCARPINE HYDROCHLORIDE | 1%; 2%; 4% | solution/drops · ophthalmic | SOMERSET THERAPS LLC | Prescription | 25 Nov 2019 |
| PILOCARPINE HYDROCHLORIDE | 1%; 2%; 4% | solution/drops · ophthalmic | AMNEAL | Prescription | 21 Sep 2020 |
| QLOSI | 0.4% | solution/drops · ophthalmic | ORASIS PHARMS | Prescription | 17 Oct 2023 |
| PILOCARPINE HYDROCHLORIDE | 1.25% | solution/drops · ophthalmic | AMNEAL | Prescription | 28 Apr 2025 |
| PILOCARPINE HYDROCHLORIDE | 1%; 2%; 4% | solution/drops · ophthalmic | FDC LTD | Prescription | 2 Oct 2025 |
| OCUSERT PILO-20 | 5MG | insert, extended release · ophthalmic | EPIC PHARMA LLC | Discontinued | 29 Jul 1974 |
| OCUSERT PILO-40 | 11MG | insert, extended release · ophthalmic | EPIC PHARMA LLC | Discontinued | 29 Jul 1974 |
| PILOPINE HS | 4% | gel · ophthalmic | ALCON | Discontinued | 1 Oct 1984 |
| PILOCARPINE HYDROCHLORIDE | 5MG | tablet · oral | PADAGIS US | Discontinued | 16 Nov 2004 |
| VUITY | 1.25% | solution/drops · ophthalmic | ABBVIE | Discontinued | 28 Oct 2021 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ISOPTO CARPINE | 00000868 | 2 % | SOLUTION · OPHTHALMIC | NOVARTIS PHARMACEUTICALS CANADA INC |
| JAMP PILOCARPINE | 02509571 | 5 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| M-PILOCARPINE | 02496119 | 5 MG | TABLET · ORAL | MANTRA PHARMA INC |
| MINIMS PILOCARPINE NITRATE | 02148463 | 2 % / W/V | DROPS · OPHTHALMIC | BAUSCH & LOMB INC |
| SALAGEN | 02216345 | 5 MG | TABLET · ORAL | AMDIPHARM LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PILOCARPINE 1% EYE DROPS | $3.44852 | per ML | 23 Sep 2026 |
| US NADAC | PILOCARPINE 2% EYE DROPS | $2.81441 | per ML | 23 Sep 2026 |
| US NADAC | PILOCARPINE 4% EYE DROPS | $3.37591 | per ML | 23 Sep 2026 |
| US NADAC | PILOCARPINE HCL 1.25% EYE DROP | $24.74 | per ML | 23 Sep 2026 |
| US NADAC | PILOCARPINE HCL 1.25% EYE DROP | $19.39133 | per ML | 23 Sep 2026 |
| US NADAC | PILOCARPINE HCL 5 MG TABLET | $0.33849 | per EA | 23 Sep 2026 |
| US NADAC | PILOCARPINE HCL 7.5 MG TABLET | $0.35404 | per EA | 23 Sep 2026 |
| US NADAC | VUITY 1.25% EYE DROP | $31.3936 | per ML | 23 Sep 2026 |
| US NADAC | VUITY 1.25% EYE DROP | $23.39475 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Pilocarpine 5mg tablets | £41.14 | 84 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Pilocarpine hydrochloride 1% eye drops | £32.10 | 10 ml | 1 Oct 2026 |
| NHS Drug Tariff | Pilocarpine hydrochloride 2% eye drops | £110.47 | 10 ml | 1 Oct 2026 |
| NHS Drug Tariff | Pilocarpine hydrochloride 4% eye drops | £69.10 | 10 ml | 1 Oct 2026 |
| NHS Drug Tariff | Pilocarpine nitrate 2% eye drops 0.5ml unit dose preservative free | £14.65 | 20 unit dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 21.4. Ophthalmological preparations > Miotics and antiglaucoma medicines · core
Acute angle closure with pupillary block; Ocular hypertension; Primary open-angle glaucoma
Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)
Safety signals and safety-related labeling changes
- US FDA 6 Apr 2023 VUITY — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.